This kit is used to in vitro qualitative detection of 14 types of ROS1 fusion gene mutations in human non-small cell lung cancer samples (Table 1). The test results are for clinical reference only and should not be used as the sole basis for individualized treatment of patients. Clinicians should make comprehensive judgments on the test results based on factors such as the patient's condition, drug indications, treatment response, and other laboratory test indicators.
ROS1 is a transmembrane tyrosine kinase of the insulin receptor family. ROS1 fusion gene has been confirmed as another important non-small cell lung cancer driver gene. As a representative of a new unique molecular subtype, the incidence of ROS1 fusion gene in NSCLC About 1% to 2% [1,2]. ROS1 mainly undergoes gene rearrangement in its exons 32, 34, 35 and 36. After it is fused with genes such as CD74, EZR, SLC34A2, and SDC4, it will continue to activate the ROS1 tyrosine kinase region. Abnormally activated ROS1 kinase can activate downstream signaling pathways such as RAS/MAPK/ERK, PI3K/Akt/mTOR, and JAK3/STAT3, thereby participating in the proliferation, differentiation and metastasis of tumor cells, and causing cancer [2].